Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging

Matthijs Oudkerk · Arthur E. Stillman · Sandra S. Halliburton · Willi A. Kalender · Stefan Möhlenkamp · Cynthia H. McCollough · Rozemarijn Vliegenthart · Leslee J. Shaw · William Stanford · Allen J. Taylor · Peter M. A. van Ooijen · Lewis Wexler · Paolo Raggi

Received: 12 February 2008 / Accepted: 6 May 2008 / Published online: 27 May 2008 © The Author(s) 2008

Abstract Current guidelines and literature on screening for coronary artery calcium for cardiac risk assessment are reviewed for both general and special populations. It is shown that for both general and special populations a zero score excludes most clinically relevant coronary artery disease. The importance of standardization of coronary artery calcium measurements by multi-detector CT is discussed.

Keywords Coronary artery calcium · Coronary artery atherosclerosis · Coronary risk assessment · Coronary artery CT

Introduction

In 1996 and 2000, the American Heart Association (AHA) issued statements on coronary artery calcium...
(CAC) quantification [1, 2]. In 2006 and 2007, several professional societies updated these statements describing new evidence related to CAC imaging [3–5]. The purpose of the present work is to summarize the rationale and content of those recommendations with regard to CAC quantification, to address differences among them and to point out controversial areas of CAC research of high clinical relevance among both asymptomatic and symptomatic persons.

Nearly all of the published clinical outcome data from CAC are based on results obtained with electron beam tomography (EBT) systems. However, these CT systems are largely no longer available and are being widely replaced with multi-detector CT (MDCT) systems. EBT, produced by one manufacturer, provided much more standardization than exists for all the various generations of MDCT systems from different manufacturers. Standardization guidelines have been proposed for MDCT [6], but are rarely used. Studies with earlier MDCT technology (4–16 slice) have demonstrated that similar mean CAC scores can be obtained with EBT and MDCT [7–12]. Nevertheless systematic differences exist which can likely affect serial measurements [6, 13, 14].

While large numbers of patients were included in the EBT outcome studies, most of these suffered from selection biases related to ethnicity, patient self-referral or referral by physicians concerned about subclinical coronary artery disease (CAD) due to the presence of risk factors. The Dallas Heart Study [15], Multi-Ethnic Study of Atherosclerosis (MESA) [16], and Rotterdam Study [17, 18] have attempted to address some of these issues. The results from general populations cannot reliably be applied to special populations. Nevertheless it is clear from many studies that in all kinds of populations, even in high-risk populations such as diabetic patients, and in both symptomatic and asymptomatic patients, the absence of coronary artery calcium (zero calcium score) excludes most clinically relevant CAD. This information is highly relevant since many individuals of subjects among the general as well as special populations have a zero calcium score.

In this paper, we review the evidence in support of the use of CAC for cardiac risk assessment in the general population as well as special populations with particular focus on the importance of a zero score. The need for standardization of CAC measurements with MDCT is also discussed.

Coronary artery calcium as a predictor of cardiac events

Most published studies addressing the issue of coronary artery calcium as a predictor of cardiac events are based on EBT data. In the ACCF/AHA Consensus Document on Coronary Artery Calcium Scoring 6 such studies were selected for review because they fulfilled sufficient criteria for outcome analysis [18–23]. From the data presented in these studies, it was concluded that coronary artery calcium scores add incremental prognostic value in the evaluation of patients at intermediate risk for a coronary event. Other studies further support this conclusion. Raggi et al. [24] screened 632 asymptomatic patients with EBT and followed them for 32 months to determine the incidence of hard cardiac events (myocardial infarction, MI and death). The majority of events occurred in individuals with high calcium scores and in individuals with scores > 75th percentile compared with age and sex matched controls. Arad et al. [19] screened 1,172 asymptomatic patients with EBT and followed them for a mean of 3.6 years to determine the incidence of cardiovascular end points (MI, death and the need for revascularization). The authors concluded that in asymptomatic adults EBT calcium scores are highly predictive of events. Pletcher et al. [25] conducted a meta-analysis of studies performed between 1980 and 2003 in ~ 13,000 asymptomatic patients screened with EBT and followed for 3.6 years or less to determine the odd ratios (OR) of hard coronary events. OR for Agatston CAC scores < 100, 100–400 and > 400 were 2.1, 4.2 and 7.2, respectively. The authors concluded that the EBT derived Agatston calcium score is an independent predictor of coronary events in asymptomatic subjects.

CAC as an indicator of coronary artery luminal stenosis

Only studies based on EBT data have addressed the issue of CAC as an indicator of coronary artery luminal stenosis. Haberl et al. [26] analyzed the value of EBT derived calcium CAC scores as an indicator of coronary luminal stenoses in 1,764 patients undergoing conventional coronary angiography. The authors concluded that EBT CAC scores are highly sensitive but moderately specific determinants of stenosis. The
ACC/AHA Expert Consensus Document on Electron-Beam CT for the diagnosis and prognosis of CAD [1] reported a pooled sensitivity of 91.8% and specificity of 55% for detection of a coronary artery stenosis > 50% after reviewing 16 selected studies comparing CAC scores and invasive angiography. Knez et al. [27] compared EBT derived Agatston CAC scores with calcium volume scores (CVS) as a predictor of coronary luminal stenoses in 2,115 patients undergoing conventional coronary angiography. The authors reported overall results similar to those already reported by others, but also concluded that the CVS are as accurate as the Agatston score for stenosis prediction. Indeed, Budoff et al. [28] utilized CVS obtained by EBT to predict the presence of coronary artery stenoses in 1,851 patients undergoing conventional coronary angiography and concluded that CVS provide incremental value in predicting the severity and extent of angiographically significant CAD.

Clinical comparison of MDCT and EBT for coronary artery calcium score measurement

Knez et al. [12] studied 99 symptomatic men (mean age: 60 years) with both MDCT (prospective triggering, Siemens Volume Zoom) and EBT imaging and found a correlation coefficient of 0.99 for CVS and 0.98 for the mass score (MS) with a mean overall variability of 17%. No significant differences for scores 1–100, 101–400, 401–1000, > 1000 were found. The authors concluded that MDCT is equivalent to EBT for CAC scoring. Becker et al. [7] compared a 4-slice MDCT (Siemens Volume Zoom) with EBT (prospective triggering) in 100 patients and calculated the Agatston score, CVS and MS. The authors concluded that the score variability is highest for the Agatston score (32%) and the correlation between MSCT and EBT is excellent for CVS and MS. Carr et al. [8] performed CT examinations with both GE Lightspeed LX/i 4-slice MDCT (retrospective gating) and EBT in 36 patients and calculated the Agatston score in all of them. The authors reported excellent correlation between scores obtained on the 2 CT systems. Horiguchi et al. [11] performed EBT and 16-MDCT with retrospective gating in 100 patients and reported a high degree of correlation between the 2 CT systems for the Agatston score ($r^2 = 0.955$), CVS ($r^2 = 0.952$) and MS ($r^2 = 0.977$). Daniell et al. [9] compared the results of EBT and 4-slice MDCT (prospective triggering, Siemens Volume Zoom) in 68 patients. EBT and MDCT scores correlated well ($r = 0.98–0.99$) with a median variability between EBT and MDCT for the Agatston score of ~25% and ~16% for CVS. Scores were higher for EBT than MDCT in approximately half of the cases, with little systematic difference between the two (median EBT-MDCT difference: Agatston score, −0.55; volume score, 3.4 mm$^3$).

Review of current guidelines on coronary artery calcification

Risk assessment in asymptomatic persons

Risk stratification algorithms such as the Framingham risk score (FRS) [29], the PROCAM score [30] or the European SCORE-system [31, 32] are used to assess an individual’s global 10-year risk. Risk factors are measured and weighed and attributed to an empirically determined absolute risk of cardiovascular events, i.e. cardiac death and MI [33]:

- low risk ≤ 1% per year or < 10% in 10 years
- intermediate risk = 1–2% per year or 10–20% in 10 years
- high risk ≥ 2% per year or > 20% in 10 years.

This classification was slightly modified by the 2004 update of NCEP guidelines (Table 1) [34]. It is argued that persons at high risk will most likely benefit from intensive risk modification, while persons at low risk are generally recommended to adhere to a healthy lifestyle and guideline-based treatment of individual risk factors when present. In persons at intermediate risk, however, there remains a diagnostic gap and further tests, such as CAC scoring, measuring intima-media thickness (IMT), the ankle arm index, or exercise stress testing may be useful in distinguishing individuals who indeed have a high risk from those at low risk, leaving hopefully few that remain at intermediate risk [33]. It should be recognized, though, that the Framingham score does not take into account life-style factors such as diet, exercise and body mass index. Neither does the score reflect a positive family history of cardiovascular disease. The extent of atherosclerotic disease burden, autonomic dysfunction, chronic inflammation, lipoprotein subfractions, blood thrombogenicity, the
myocardial propensity to develop life-threatening arrhythmias, and immeasurable genetic factors are also not part of conventional risk assessment. Measuring the atherosclerotic sequelae of life-long global exposure to all risk factors by virtue of measuring the extent of the disease in its early subclinical stages may overcome this limitation. The detection of calcified atherosclerosis is a general surrogate of total atheroma burden. It is noted however, that the extent of coronary calcification systematically differs among ethnic populations and by gender.

The focus of current guidelines on CAC scoring

The AHA Scientific Statement on “Assessment of Coronary Artery Disease (CAD) by Cardiac Computed Tomography” [3] reviewed scientific data for cardiac CT related to imaging of CAD and atherosclerosis in symptomatic and asymptomatic subjects, including a detailed description of technical aspects and radiation exposure of CAC CT and non-invasive CT angiography using EBT and MDCT. According to AHA standards, recommendations were classified (Class I, IIa, IIb and III) and the level of evidence (A, B, or C) was provided (see http://circ.ahajournals.org/manual/manual_IIstep6.shtml).

The ACC/AHA 2007 Clinical Expert Consensus Document [4] discussed the role of CAC quantification with respect to (1) identifying and modifying coronary event risk in asymptomatic subjects, (2) modifying clinical care and outcomes of symptomatic patients with suspected CAD and (3) understanding the role of CAC CT in selected patient sub-groups, including women, ethnic groups, and patients with renal disease or diabetes. (4) The clinical value of serial CAC CT, cost-effectiveness of CAC CT, and clinical implications of incidental findings were also addressed.

The purpose of the 2006 Appropriateness Criteria Statement [5] was to create, review and categorize appropriateness criteria for cardiac CT and also cardiac magnetic resonance imaging (MRI) with regard to detection of CAD, cardiovascular risk stratification, as well as cardiac structure and function assessment. Members of the expert group assessed the risks and benefits of the imaging tests for several indications and clinical scenarios and scored them based on a scale of 1–9:

- \( 7–9 = \text{appropriate: the test is generally acceptable and is a reasonable approach} \)
- \( 4–6 = \text{uncertain: uncertain indication or clinical setting} \)
- \( 1–3 = \text{inappropriate: the test is generally not acceptable/is not a reasonable approach} \)

Indications in the latter statement were derived from common applications or anticipated uses of cardiac CT and MRI. Working group panelists rated each indication based on the ACC Methodology for Evaluating the Appropriateness of Cardiovascular Imaging [35].

### Indications for CAC scoring in asymptomatic individuals

In the past several years, numerous publications have reported on the incremental prognostic value of CAC over measured conventional risk factors in large series of patients including asymptomatic population-based cohorts [18, 20–23, 36]. The relative risk of coronary events increased with increasing CAC burden (Fig. 1).

<table>
<thead>
<tr>
<th>Ten-year risk categories</th>
<th>Definition of risk category</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk</td>
<td>CAD(^a), CAD-risk equivalents(^b), ( \geq 2 ) major risk factors(^c), 10-year-risk &gt; 20%</td>
</tr>
<tr>
<td>Moderately high risk</td>
<td>( \geq 2 ) major risk factors but 10-year CAD risk 10–20%</td>
</tr>
<tr>
<td>Moderate risk</td>
<td>( \geq 2 ) major risk factors but 10-year CAD risk &lt; 10%</td>
</tr>
<tr>
<td>Low risk</td>
<td>0–1 major risk factor and 10-year CAD risk &lt; 10%</td>
</tr>
</tbody>
</table>

**Table 1** Absolute risk categories “NCEP-Update 2004”, modified from [34]

**Definitions**

- **CAD**: coronary artery disease
- \(^a\) History of myocardial infarction, coronary revascularisations or myocardial ischemia
- \(^b\) Includes diabetes mellitus, stroke, TIA or carotid artery stenosis > 50%, symptomatic peripheral artery disease or abdominal aortic aneurysm
- \(^c\) Smoking, hypertension, high LDL-cholesterol/low HDL-cholesterol, age (men > 45 years., women > 55 years), and premature family history of CAD (first grade family member, i.e. men < 55 years., women < 65 years)
The majority of the expert writing committees agree that it may be reasonable to consider use of CAC measurement in asymptomatic intermediate risk patients, i.e. 10–20% coronary events in 10 years. These patients might be reclassified to a higher risk status based on a high CAC score, and subsequent patient management may be modified (Fig. 2). In the ACC Appropriateness Criteria Document, notably published prior to the most recent AHA and ACC statements and additional prospective CAC scoring studies, CAC scoring was considered appropriate only for very few indications. However, all of them were given a rating of “uncertain”, most notably CAC scoring for risk assessment in the general population at moderate (score 6) or high (score 5) CAD Framingham risk. In patients with a low or a high 10 year risk of coronary events, i.e. < 10% or > 20% in 10 years, CAC quantification is not recommended; in low risk individuals, even a high CAC score does not generally elevate this person’s risk above the threshold to initiate therapy [4]. Yet, life-time risk may be elevated in 18% and 20% of asymptomatic men and women, respectively, who have a high CAC score, i.e. CAC > 400 or > 75th percentile, despite a low FRS [37]. Persons with a high 10-year risk are candidates for intensive risk modification based on current NCEP guidelines [34], and there is no evidence that a low CAC score substantially reduces this risk. This also holds for persons with risk equivalents. The performance of serial (follow-up) calcium scoring examinations was not recommended.

**Atherosclerotic disease quantification in patients with chest pain**

In symptomatic patients, diagnostic tests may be used for risk stratification, but the primary initial objective is to identify or rule out obstructive CAD. Especially in young persons with atypical chest pain, non-atherosclerotic non-obstructive coronary disease such as myocardial bridging, coronary anomalies, coronary vasospasm, intramyocardial small vessel disease, or non-coronary heart disease (CHD) such as cardiomyopathy, valvular heart disease, pericardial disease, aortic disease, pulmonary disease, etc. must be considered as differential diagnoses. Persons with an intermediate pretest-likelihood of obstructive CAD, i.e. between 20 and 80%, are most likely to benefit from additional testing [38].

Functional tests such as treadmill, exercise or pharmacological nuclear stress tests or stress-echo-cardiography are used to induce myocardial ischemia in patients with flow limiting coronary obstruction. In contrast, CAC CT is aimed at estimating coronary plaque severity and the associated likelihood of a flow-limiting lesion. These two approaches, the former functional and the latter morphological, are distinctly different and have inherently different reasons for false positive and false negative results.

The presence of CAC is almost 100% sensitive for the presence of atherosclerotic coronary plaque but not specific for flow limiting plaque, as both obstructive and non-obstructive lesions can contain calcific deposits in the vessel wall. However, increasing calcium scores are associated with an increasing likelihood of both obstructive disease, and an increased severity.
Moderately high coronary calcium scores (approximately 150) in symptomatic patients are associated with a roughly 80% sensitivity and specificity for the presence of an obstructive coronary artery lesion (among patients referred to coronary angiography) [26, 28] an accuracy that is similar in magnitude to conventional stress tests [38, 39]. Consistent with these data are findings from myocardial perfusion scintigraphy in which only 2% of patients with a CAC score < 100 were shown to have a positive nuclear stress test [40]. A clinical application of these relationships has been demonstrated among emergency department patients with chest pain, in whom a zero calcium score was associated with a very low risk of cardiovascular events [41]. Caution in the interpretation of zero calcium scores is warranted among individuals with a high pretest probability for CAD (e.g., young smokers) in whom false negative studies may be observed [42].

In summary, the majority of expert writing committee members agreed that patients at low risk of CAD by virtue of atypical cardiac symptoms may benefit from CAC testing to help exclude the presence of obstructive CAD. CAC scoring may be a useful filter prior to invasive angiography or further stress testing [43, 44]. However, more data on direct comparisons with established forms of stress testing are needed. Currently, additional non-invasive testing in persons with a very high CAC score, e.g., > 400 is not recommended as there is no evidence that such additional testing will improve appropriate selection of candidates for therapy. CAC CT was classified as “Class IIb, Level of Evidence: B” when used to rule out obstructive CAD in patients with chest pain with equivocal or normal ECGs and negative cardiac enzymes, and in symptomatic patients in the setting of equivocal exercise stress tests [3].

Other clinical scenarios: Serial imaging of CAC to assess disease progression is currently not indicated by the existing guidelines [3]; this issue is discussed later herein. Existing evidence on CAC CT has mostly been gathered from studies in Caucasian men and caution is warranted in extrapolating existing data to other ethnic groups or women.

Implications for therapy

The NCEP/ATP III Guidelines have incorporated CAC CT as a complementary test to modify treatment intensity: “Measurement of coronary calcium is an option for advanced risk assessment in appropriately selected persons. In persons with multiple risk factors, high coronary calcium scores (e.g., > 75th percentile for age and sex) denote advanced coronary atherosclerosis and provide a rationale for intensified LDL-lowering therapy. Moreover, measurement of coronary calcium is promising for older persons in whom the traditional risk factors lose some of their predictive power [34]. The use of CAC percentile ranks, as advocated in the NCEP guidelines, is especially important in young individuals whose absolute scores may be low, yet “high-for-age”, indicating a high life-long risk, even though short-term risk over the next 5–10 years may be low. As risk factor modification in high-risk subjects should be initiated as early as possible, such persons are likely appropriate candidates for intensive risk modification—a notion that needs to be further confirmed by prospectively collected outcome data.

Limitations

There is currently little evidence that CAC CT and knowledge of CAC score severity has an impact on the advice physicians give to patients or on patients’ adherence to prescribed risk factor modification efforts [45]. Further, CAC CT may improve risk stratification in selected populations, but currently the data are limited that CAC CT improves outcome. Accordingly, current evidence does not support lowering treatment intensity in intermediate risk subjects even if the CAC score is zero [4].

Summary

Current guidelines propose the use of CAC CT to improve risk stratification in subjects at intermediate 10-year risk of incident coronary events. The present writing committee agrees with this general recommendation.

Race and calcium score

There is still limited knowledge of the predictive value of CAC in non-Caucasians. It has been well documented that there is a notable difference in CAC accumulation not only between men and women, but
also between subjects of different ethnicities and races. Doherty et al. [46] using subtraction fluoroscopy first noted a significantly lower prevalence of CAC in Blacks than Whites (35.5 vs. 59.9%, \( P = 0.0001 \)) and warned of the different prognostic significance of CAC in these races. Indeed, during a follow up of 70 ± 13 months, 23.7% of the black and 14.8% of the white screened population suffered an incident cardiovascular event (odds ratio: 2.16, 95% CI: 1.34–3.48). The significant difference in prevalence and distribution of CAC assessed by CT in 4 races in the US, was recently confirmed by the Multi-Ethnic Study of Atherosclerosis. Bild et al. [16] showed that the prevalence of CAC on cardiac CT (score \([0) was highest in Whites followed by Chinese, Hispanics and finally Blacks. Santos et al. [47] showed that North American Caucasian subjects have more CAC than Caucasian subjects from Brazil and Portugal despite the higher prevalence of risk factors in the latter two ethnic groups. Interestingly, despite a substantial genetic similarity between Brazilian and Portuguese patients, and the presence of more smokers among the latter, Brazilians had a greater extent of coronary artery calcium than Portuguese subjects. These findings mirrored the national mortality and morbidity statistics indicating a greater cardiovascular event rate in the North American, followed by the Brazilian and finally the Portuguese population.

Despite the noted differences in CAC scores, there is currently limited evidence of the prognostic significance of CAC in different races. Detrano et al. [48] showed that CAC is a strong predictor of cardiovascular death, non-fatal MI, angina and revascularization (total events = 162) in all 6,722 MESA patients independent of race. Furthermore, CAC added incremental prognostic value beyond traditional risk factors for the prediction of events.

Recently, Nasir et al. [49] evaluated the use of CAC to predict all-cause mortality in 14,812 patients belonging to the same four races considered in MESA (505 deaths in 10 years of follow-up). Once again the prevalence of CAC was highest in Whites, although Blacks and Hispanics had a greater clustering of risk factors for CAD. Despite a lower prevalence of CAC and lower scores compared to the other races, black patients had the highest mortality rates even after multivariable adjustment for clinical risk factors and baseline CAC score (\( P < 0.0001 \)). Compared with Whites, the relative risk of death was 2.97 (CI: 1.87–4.72) in Blacks, 1.58 (CI: 0.92–2.71) in Hispanics and 0.85 (CI: 0.47–1.54) in Chinese individuals. A 50-year-old black patient with a CAC score > 400 had an estimated loss of 7 years of life, as opposed to 2.5 years of life for a white patient with the same score.

Therefore, it would appear appropriate to consider CAC a good marker of risk in all races so far investigated, although the prognostic significance of score categories varies between racial groups. This underscores the importance of racial specific risk categories defined according to CAC score thresholds. An attempt at defining such categories was recently published by Sirineni et al. [50]. In their publication the authors suggested substituting the chronological age of a patient undergoing CAC screening for his vascular age. The vascular age can be assessed according to the median CAC score for a subject of the same age, race and sex. For example a 50-year-old black man with a CAC score of 40 should be considered ~ 20 years older than his chronological age, since 40 is the median score of a 70-year-old black man in MESA. On the other hand, a score of 40 adds only 11 years of age to a 50-year-old white man. The prognostic validity of this novel approach is still awaiting confirmation in prospective studies.

### The value of coronary artery calcium in the elderly population

The assessment of coronary calcification may have particular value in the elderly population. The potential for prevention of CHD in older adults is large, since even a small reduction in risk factor levels results in a considerable reduction in event rates. However, to identify asymptomatic elderly in the population at the highest risk of CHD is challenging. Office-based risk score algorithms like the FRS [29] and the European SCORE [31] have an upper age threshold that limits their applicability to older adults. Furthermore, the predictive power of risk factors diminishes with increasing age [51–53]. Finally, age becomes the predominant factor in the algorithm in older adults, despite the fact that a fixed weight attributed to age does not take into account the individual variation in coronary plaque burden. On the basis of risk factors and age, the true CHD risk may be miscalculated, and this may lead to inaccurate
selection of elderly for aggressive risk factor modification.

CAC reflects the life-time impact of all atherosclerosis risk factors, both known and unknown, on the arterial wall [54]. Thus, this non-invasive measurement can provide a more accurate estimate of the accumulated plaque burden and CHD risk. So far, one population-based study has focused on the predictive value of CAC in the elderly: the Rotterdam Coronary Calcification Study (mean age, 71 years) [18]. During a mean follow-up period of 3.3 years, 50 of the 1,795 initially asymptomatic subjects had a coronary event. Increasing CAC score categories showed relative risks for CHD up to 8.2 (95% CI: 3.3–20.5) for a CAC score above 1,000, compared to absent or low CAC score (0–100). Similar relative risks were found after adjustment for risk factors and in asymptomatic individuals over 70 years of age. Of interest, there was a very low probability of events in subjects with a low CAC score (0–100). Furthermore, irrespective of the Framingham risk category (low-to-intermediate or high risk), increasing CAC score categories were strongly associated with the risk of events. Thus, a low CAC score in elderly may be as valuable a finding as in younger subjects. These results indicate that the CAC score is a very promising measurement to improve cardiovascular risk stratification in the elderly. In a recent publication, Abbott et al. [55] reported on 224 very old (age 84–96) Japanese men living in Hawaii followed for an average of 2.5 years after CAC imaging. A total of 17 deaths occurred during 2.5 years of follow-up and no death occurred in patients with a CAC score < 10. As shown in the study by Vliegenthart et al. [18], the death rate increased significantly as the CAC score increased (P < 0.001). Finally, Newman et al. [56] measured CAC and carotid IMT in 559 patients (336 women) age 70–99 years. The top quartile of each measurement was associated with ~ 2-fold increased risk of a combined cardiovascular disease end-point.

Other population prospective studies have been conducted in a wide age range [20–22, 24, 36, 57]. Most of these studies did not specifically address the predictive value of CAC in older age. In a study by LaMonte et al. [22], CHD event rates adjusted for gender were presented in different age groups. In subjects over 65 years of age, a graded increase in event rates was seen for CAC scores ≥ 100 and ≥ 400 (7.1 and 8.2 per 1000 person-years, respectively). Conversely, absence of CAC was associated with a very low event rate (0.9 per 1,000 person-years).

Summary

These data support the notion that CAC screening may be used in all age groups to adjust the relative risk level. They must, however, be considered preliminary; more research will be needed to demonstrate that expensive medical therapies can be withheld in the elderly with risk factors in the absence of CAC and to establish the best approach to managing older, asymptomatic patients with extensive CAC.

Diabetes mellitus and coronary artery calcium

Patients suffering from diabetes type–2 have been shown to harbor larger amounts of CAC than non-diabetic patients with the metabolic syndrome [58] and subjects of similar age and otherwise similar risk factor profile [58, 59]. The extent of CAC in patients with type-2 diabetes is similar to that of patients with established CAD but without diabetes, diabetic women harbor as much CAC as diabetic men [60, 61], and younger diabetic individuals have a plaque burden comparable to that of older non-diabetic individuals [62]. All of this confirms the clinical evidence that diabetes mellitus is associated with a very high prevalence of CAD; it negates the advantage of women over men and of youth over older age in prevalence and extent of atherosclerosis. Hoff et al. utilized a large database to calculate the age and gender normative (percentile) distribution of calcium scores in asymptomatic (self-reported) diabetic individuals [62].

Olson et al. [63] investigated the presence of CAC and prior CAD in 302 patients with diabetes mellitus type-1 and a history of MI, angina, or evidence of ischemia on stress testing or surface electrocardiograms. Among the subjects free of clinical CAD, 5% had a CAC score ≥ 400 (large atherosclerosis burden), as opposed to 25% of the subjects with prior angina or objective evidence of myocardial ischemia and 80% of the patients with MI or luminal stenoses on invasive angiography. CAC showed a sensitivity
of 84% and 71% for clinical CAD in men and women, respectively, and 100% sensitivity for MI and obstructive CAD.

Limited data exist on outcome related to CAC in diabetic patients. Wong et al. [64] performed CAC screening and stress myocardial perfusion imaging (MPI) in 1043 patients, 313 of whom were affected by either diabetes mellitus ($N = 140$) or the metabolic syndrome ($N = 173$). In patients with a CAC score $< 100$, the prevalence of stress induced MPI abnormalities was very low ($\sim 2\%$). However, in the presence of a metabolic disorder (diabetes mellitus or the metabolic syndrome) a CAC score between 100 and 399 or greater than 400 was associated with a greater incidence of ischemia than in patients without a metabolic disorder (13% vs. 3.6%, $P < 0.02$, and 23.4% vs. 13.6%, $P = 0.03$, respectively). Similarly, Anand et al. [65] performed sequential CAC screening and MPI in 180 type-2 diabetic patients. The incidence of myocardial ischemia was directly proportional to the CAC score. For type-2 diabetic patients with a CAC score of 0, 11–100, 101–400, 401–1,000, and $> 1,000$, the incidence of myocardial ischemia on stress MPI was 0%, 18%, 23%, 48%, and 71%, respectively. In summary, based on the Wong [64] and Anand data [65], type-2 diabetic patients with a CAC score $> 100$ are expected to have an increased frequency of ischemia on MPI.

Two outcome studies addressed the question of whether CAC constitutes a risk for events in asymptomatic patients but came to opposite conclusions. The South Bay Heart Watch (SBHW) was a prospective cohort study designed to determine the relation between radiographically detectable CAC and cardiovascular outcome in high-risk asymptomatic adults [66]. Thirteen hundred and twelve asymptomatic subjects $\geq 45$ years old with cardiac risk factors were recruited via mass-mailing advertisement in the Los Angeles area; of these 19% were diabetic patients. In a sub-analysis of the main database after a mean follow-up of 6 years, Qu et al. [66] found an increased risk of cardiovascular events (death, MI, stroke and revascularizations) in diabetic patients compared to non-diabetic subjects in the presence of CAC. However, the risk did not increase significantly as the CAC score increased. Raggi et al. [67] utilized a database of 10,377 asymptomatic individuals (903 diabetic patients), followed for an average of 5 years after CAC screening. The primary end-point of the study was all-cause mortality. The authors showed that the risk of all-cause mortality was higher in diabetic patients than non-diabetic subjects for any degree of CAC and the risk increased as the score increased. Additionally, the absence of CAC predicted a low short-term risk of death ($\sim 1\%$ at 5 years) for both diabetic patients and non-diabetic subjects [67]. Hence, both the presence and absence of CAC were important modifiers of risk even in the presence of established risk factors for atherosclerosis such as diabetes mellitus. This suggests that there is a great heterogeneity among diabetes mellitus patients and that risk stratification may be of benefit even in patients considered to be at high-risk of atherosclerosis complications.

Summary

The preceding discussion suggests that CAC imaging techniques may be very helpful to the practicing physician faced with the dilemma of accurate risk assessment even in diabetic patients at high risk. However, as is the case with other subsets of patients, further research will be needed to confirm the prognostic role of CAC in diabetes mellitus.

Renal failure and coronary artery calcium

Both EBCT and MSCT have been utilized in the recent past to investigate the natural history and pathogenesis of CAC, as well as the impact of different therapeutic strategies in chronic kidney disease (CKD). Evidence indicates that as the estimated glomerular filtration rate (eGFR) declines the prevalence of CAC increases. In fact, the prevalence of CAC was reported to be 40% in 85 pre-dialysis patients as opposed to 13% in controls with normal renal function [68]. In a prospective study of 313 high-risk hypertensive patients a reduced eGFR was shown to be the major determinant of the rate of progression of CAC (ORs for calcium progression in the group with $eGFR \leq 60 \text{ ml/min: } 2.1; \text{ 95\% CI: } 1.2–3.7$) [69]. Consistent with these findings, Sigrist et al. [70] reported a prevalence of CAC of 46% in 46 pre-dialysis patients compared to 70% and 73% respectively in 60 hemodialysis and 28 peritoneal dialysis patients ($P = 0.02$). Hence, it appears that the
prevalence of CAC increases with declining renal function and after initiation of dialysis. Of note, CAC was reported in ~ 60% of patients new to hemodialysis [71] and in as many as 80–85% of adult prevalent hemodialysis patients [72] in two prospective, randomized studies. In a small longitudinal study, the baseline CAC score measured by EBT in 49 prevalent hemodialysis patients was on average 2- to 5-fold higher than in age and sex matched individuals with established CAD. A repeat CT after an interval of 12 months showed significant progression of CAC \( (P < 0.05) \) [73].

A number of factors have been associated with progression of CAC in dialysis patients. Associations with age and duration of dialysis [72, 74], diabetes mellitus [72] abnormalities of mineral metabolism [75–77] as well as use and dose of calcium based phosphate binders [78, 79] have all been reported. To investigate the impact of therapy for hyperphosphatemia on the progression of CAC a randomized clinical trial compared the effect of Sevelamer (Genzyme, Cambridge, MA USA—a non-absorbable polymer with gut phosphate binding ability) and calcium-based phosphate binders in 200 hemodialysis patients for 1 year [78]. Throughout the study both drugs provided a comparable phosphate control (mean phosphate = 5.1 mg/dl), although a significantly higher serum calcium concentration \( (P = 0.002) \) was noted in the calcium-salts treated arm. At study completion Sevelamer treated subjects were less likely to experience CAC progression (median absolute progression of CAC score 0 vs. 36.6, \( P = 0.03 \) and aorta 0 vs. 75.1, \( P = 0.01 \), respectively) [78].

In a smaller series of 129 patients new to hemodialysis [80], subjects treated with calcium-containing phosphate binders showed a more rapid and more severe increase in CAC score compared with those receiving Sevelamer \( (P = 0.056 \) at 12 months, \( P = 0.01 \) at 18 months) [80]. In the same series, all-cause mortality was strongly associated with the baseline CAC score, and was significantly lower in the Sevelamer arm after 4.5 years of follow up \( (P = 0.02) \) [71]. Even more surprisingly mortality was extremely low (3.9%/year) in patients with 0 calcium score. This stands in contrast with a reported mortality of ~ 20–25%/year in patients undergoing hemodialysis. CAC scores were also shown to be predictive of an unfavorable outcome in dialysis patients by Matsuoka et al. [81]. The authors followed 104 chronic hemodialysis patients for an average of 43 months after a screening EBT. Patients were divided in two groups according to a baseline CAC score falling below or above the median for the group \( (score = 200) \). The 5-year cumulative survival was significantly lower for patients with a CAC score > 200 than for those with a score < 200 (67.9% vs. 84.2% \( P = 0.0003 \)).

Summary

CAC appears to be predictive of an adverse outcome in CKD patients and its absence has been linked with a very low event rate.

The value of the ZERO calcium score—ASYMPTOMATIC PATIENTS

The presence of coronary calcification is, especially with advancing age, a sensitive but unspecific finding. As discussed above, many studies have emphasized the graded increase in CHD risk with increasing calcium scores. However, an even more clinically relevant finding may be the absence of CAC. In a large population of over 10,000 individuals screened for CAC, all-cause mortality was assessed during a 5-year follow-up period. With a zero or very low (< 10) calcium score, the investigators reported a very low probability of mortality, \( \sim 1.0\% \) at the end of follow-up [82]. This finding was confirmed in a study by Budoff in 25,253 individuals, in which only 0.4% of the individuals with a negative calcium score died during almost 7 years of follow-up, compared to 3.3% of individuals with a positive CAC score [57]. In prospective studies in which CHD was used as outcome measure, a zero or very low calcium score was associated with a very low probability of events during follow-up [21, 23, 24, 36, 83]. Church et al. reported a relative risk of coronary events in subjects without CAC compared to those with a positive calcium score of 0.13 (95% CI, 0.06–0.30) [83]. Cumulative incidences in studies with a follow-up period of 3–5 years ranged between 0.1% and 0.7% (Table 2). One study showed a somewhat higher cumulative incidence of 4.4% during more than 6 years [20]. This may be partly explained by the different CT protocol (6 mm slicing) which may have resulted in missing calcified lesions.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>N total</th>
<th>N subgroups</th>
<th>Mean age ± SD (years)</th>
<th>Lowest calcium score category</th>
<th>Percentage in lowest category (%)</th>
<th>Mean follow-up ± SD (years)</th>
<th>Outcome</th>
<th>Cumulative incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raggi et al. [24]</td>
<td>2000</td>
<td>632</td>
<td></td>
<td>52 ± 9</td>
<td>0</td>
<td>46</td>
<td>2.7 ± 0.6</td>
<td>MI/cardiac death</td>
<td>0.3</td>
</tr>
<tr>
<td>Shaw et al. [82]a</td>
<td>2003</td>
<td>10,377</td>
<td></td>
<td>53 ± 10</td>
<td>0–10</td>
<td>57</td>
<td>5.0 ± 3.5</td>
<td>All cause mortality</td>
<td>1.0</td>
</tr>
<tr>
<td>Raggi et al. [84]a</td>
<td>2004</td>
<td>10,377</td>
<td>4,191 Women</td>
<td>55 ± 11</td>
<td>0–10</td>
<td>68</td>
<td>5.0 ± 3.5</td>
<td>All cause mortality</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6,186 Men</td>
<td>52 ± 11</td>
<td></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raggi et al. [67]a</td>
<td>2004</td>
<td>10,377</td>
<td>903 Diabetics</td>
<td>57 ± 10</td>
<td>0</td>
<td>30</td>
<td>5.0 ± 3.5</td>
<td>All cause mortality</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9,474 Non-diabetics</td>
<td>53 ± 10</td>
<td></td>
<td>51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaw et al. [42]a</td>
<td>2006</td>
<td>10,377</td>
<td>4,113 Smokers</td>
<td>53 ± 10</td>
<td>0–10</td>
<td>About 49</td>
<td>5.0 ± 3.5</td>
<td>All cause mortality</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6,264 Non-smokers</td>
<td>54 ± 11</td>
<td></td>
<td>About 63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kondos et al. [21]</td>
<td>2003</td>
<td>5,635</td>
<td>1,484 Women</td>
<td>54 ± 9</td>
<td>0</td>
<td>49</td>
<td>3.0 ± 1.0</td>
<td>MI/CHD death</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4,151 Men</td>
<td>50 ± 9</td>
<td></td>
<td>26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greenland et al. [20]</td>
<td>2004</td>
<td>1,029</td>
<td></td>
<td>66 ± 8</td>
<td>0</td>
<td>31</td>
<td>6.3 ± 1.5</td>
<td>MI/CHD death</td>
<td>0.3</td>
</tr>
<tr>
<td>Arad et al. [36]</td>
<td>2005</td>
<td>4,613</td>
<td></td>
<td>59 ± 6</td>
<td>0</td>
<td>33</td>
<td>4.3</td>
<td>MI/CHD death/ revascularizations</td>
<td>0.5</td>
</tr>
<tr>
<td>Vliegenthart et al. [18]</td>
<td>2005</td>
<td>1,795</td>
<td></td>
<td>71 ± 6</td>
<td>0–100</td>
<td>50</td>
<td>3.3 ± 0.8</td>
<td>MI/CHD death</td>
<td>0.7</td>
</tr>
<tr>
<td>Taylor et al. [23]</td>
<td>2005</td>
<td>1,983</td>
<td>356 Women</td>
<td>43 ± 3</td>
<td>0</td>
<td>92</td>
<td>3.0 ± 1.4</td>
<td>MI/CHD death/unstable angina</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1,627 Men</td>
<td></td>
<td></td>
<td>78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Church et al. [83]b</td>
<td>2007</td>
<td>10,746</td>
<td></td>
<td>54 ± 10</td>
<td>0</td>
<td>53</td>
<td>3.5 ± 1.4</td>
<td>MI/CHD death</td>
<td>0.1</td>
</tr>
<tr>
<td>LaMonte et al. [22]f</td>
<td>2005</td>
<td>10,746</td>
<td>3,911 Women</td>
<td>54 ± 10</td>
<td>0</td>
<td>71</td>
<td>3.5 ± 1.4</td>
<td>MI/CHD death</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6,835 Men</td>
<td></td>
<td></td>
<td>39</td>
<td></td>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>Budoff et al. [57]</td>
<td>2007</td>
<td>25,253</td>
<td></td>
<td>56 ± 11</td>
<td>0</td>
<td>44</td>
<td>6.8 ± 3.0</td>
<td>All cause mortality</td>
<td>0.4</td>
</tr>
</tbody>
</table>

CHD: coronary heart disease; MI: myocardial infarction; SD: standard deviation

a Same study, analysis in different subgroups
b Same study, analysis in different subgroups

Cumulative incidence derived from published data or calculated
Four studies have specifically compared the prognosis for men and women in the absence of CAC. Raggi et al. found no difference in all-cause mortality after 5 years of follow-up in over 4,000 women and over 6,000 men with a very low CAC score (< 10): 1.6% vs. 1.5% [84]. Recently, the results from three studies in which CHD was the outcome [21–23], were used in a meta-analysis [85]. In total, the analysis included 3,862 women and 5,548 men with absent or minimal CAC. The annual CHD event rate was very similar in women and men: 0.2% vs. 0.3%. When only women and men with no CAC were studied, rates were somewhat lower (0.16% vs. 0.27%) but again not significantly different. Thus, absent or very low CAC score carries the same prognostic value in both genders.

Interestingly, even in the presence of cardiovascular risk factors, the negative predictive value of absent or minimal CAC appears to be very high. In the aforementioned study in which all cause mortality was the outcome [82], further investigations were performed according to smoking status and diabetes status of the participants [42, 67]. Absence of CAC was noted in about 30% of individuals with diabetes, and in 50% of smokers. Little or no CAC was associated with a near 100% survival in non-smokers as well as smokers, and non-diabetic as well as diabetic subjects.

As discussed in the previous section, Block et al. [71] reported a very low mortality rate for hemodialysis patients without evidence of CAC (3.9%/year); this is in contrast with the extremely high mortality rate (~ 25–30%/yearly), typically quoted for this category of patients. Thus, the absence of CAC may be an important modifier of the risk of events even in the presence of cardiovascular risk factors. The high negative predictive value of a zero CAC score is extremely valuable, considering that a large number of asymptomatic individuals have no CAC. In various studies, absence of CAC was noted in 26–92% of individuals, depending on the age of the individuals. Hence, a zero CAC score may have important implications in daily clinical practice and on a population level. The most important question from a population and societal point of view is whether individuals without CAC should be considered at low risk, even in the presence of cardiovascular risk factors, and therefore be spared therapies such as aspirin and cholesterol-lowering medications. Although the current evidence is substantial, such a notion cannot be endorsed at this time in the absence of prospective, randomized trials.

**The value of ZERO calcium score—SYMPTOMATIC PATIENTS**

Calcium score and prediction of obstructive coronary artery disease on angiography

As outlined above, a negative CAC score has a high negative predictive value in asymptomatic patients of both genders and even in patients with risk factors such as smoking, diabetes or renal failure. In symptomatic patients where CAD is suspected, can a zero or a minimal CAC score (e.g., < 10) be used as a filter to rule out obstructive CAD? Several investigators have addressed this point. Becker et al. studied 1,347 symptomatic subjects with suspected CAD [86]. Sensitivity, specificity and predictive accuracy were calculated for different calcium thresholds for prediction of CAD. In 720 (53%) subjects, invasive angiography revealed a lumen diameter stenosis greater than 50%. Patients with obstructive CAD had significantly higher total calcium scores than patients without CAD ($P = 0.001$). The overall sensitivity of any CAC score to predict stenosis was 99%, with a specificity of 32%. An absolute score cutoff $\geq 100$ and an age and sex specific score $> 75$th percentile were identified as the cutoff levels with the highest sensitivities (86–89%) and lowest false positive rates (20–22%). Absence of CAC was highly accurate for exclusion of CAD in subjects older than 50 years (negative predictive value $= 98\%$). The authors concluded that the presence of CAC on MDCT in symptomatic patients is accurate for prediction of obstructive CAD and that its absence is associated with a high negative predictive value for exclusion of CAD.

Several other studies investigated the presence of non-calcified plaques and obstructive lesions in patients with a low or zero CAC score. Cheng et al. assessed the presence and severity of non-calcified coronary plaques on 64-MDCT coronary angiography in 554 symptomatic patients with low to intermediate pre-test likelihood for CAD and zero or low CAC.
score (low score: men, score < 50; women, score < 10) [87]. The authors intended to elucidate how well absence of CAC predicts the absence of obstructive non-calcified coronary artery plaque (NCAP). Compared with patients with absent CAC, those with a low CAC score had markedly increased rates of critical luminal stenoses (8.7% vs. 0.5%, \( P < 0.001 \)). The authors concluded that in symptomatic patients with low to intermediate pre-test probability of CAD, absence of CAC predicts very low prevalence of occlusive NCAP. Nonetheless, low but detectable CAC scores were significantly less reliable in excluding the presence of plaque that at times could be obstructive.

Leschka et al. recently studied the potential of using the CAC score to improve the diagnostic accuracy of MDCT angiography [88]. They evaluated 74 consecutive patients who underwent CAC scoring, MDCT angiography and invasive angiography. Segments that were not evaluable on MDCT angiography were considered to be false-positive. When using CAC scores of 0 to exclude stenoses and \( \geq 400 \) to predict stenosis for segments with non-evaluvative segments, the per-patient sensitivity and specificity improved from 98% and 87% to 98% and 100%, respectively. Only the 0 CAC score was found to be helpful to exclude stenoses as a high CAC score often corresponds to more than one stenosis in the coronary artery tree.

In a study by Rubinshtein et al. [89], the severity of CAD was examined using 64-MDCT angiography in patients who underwent testing due to chest pain syndromes and had a zero or low CAC score. Of 668 consecutive patients, 231 had a low score (\( \leq 100 \)) or absent CAC. Obstructive CAD was present in 9 of 125 patients (7%) with a 0 CAC score, and in 18 of 106 (17%) with a low score (CAC: 1–100).

**Summary**

In conclusion, absent CAC seems to be an excellent filter for exclusion of obstructive CAD in symptomatic patients with intermediate to high pre-test likelihood of obstructive CAD. A low CAC score, however, is more controversial as a number of studies showed that the presence of non-calcified and potentially obstructive lesions is higher in patients with low CAC scores and symptoms compared to patients with a score of zero.

The value of zero calcium score to rule out CAD in symptomatic patients: comparison to treadmill stress testing and nuclear stress tests

In discussing the potential value of a zero CAC score in symptomatic patients for a reliable exclusion of CAD, other non-invasive tests like ECG stress testing or nuclear stress testing have to be considered. Exercise stress testing is often used as the initial non-invasive diagnostic test in symptomatic patients with suspected obstructive CAD. Positive standard ECG criteria are quite specific for obstructive CAD, but there may be a substantial number of false negative tests, including patients with severe disease. Also, exercise stress tests frequently yield equivocal results. Lamont et al. assessed the value of combining CAC screening with a stress test to reduce the high false-positive rate seen with treadmill stress test (TMST) alone [90]. A CAC score was obtained by EBT in 153 symptomatic patients who underwent coronary angiography because of a positive TMST. The TMST false-positive rate was 27% (41 of 153). In these patients, a CAC score of zero resulted in a negative predictive value of 93%. The authors concluded that the absence of CAC reliably identified patients with a false-positive TMST result. Raggi et al. [44] showed that in symptomatic patients with low to intermediate pretest probability of disease (5-50%), a CAC score of zero can be reliably used to exclude obstructive CAD and that calcium scoring as the initial test to investigate presence of CAD provides a substantial cost benefit over a pathway based on exercise stress testing. Berman et al. [40] described the relationship between stress-induced myocardial ischemia on single-photon emission computed tomography (SPECT) perfusion studies and CAC. Including a total of 1,195 patients without known CAD, 51% asymptomatic, the frequency of ischemia by SPECT was compared to the magnitude of CAC. The frequency of ischemic SPECT was < 2% with CAC scores < 100 and increased progressively with CAC > 100 (\( P \) for trend < 0.0001). Patients with symptoms and CAC scores > 400 had higher likelihood of myocardial ischemia versus those without symptoms (\( P < 0.025 \)). The authors concluded that ischemic SPECT is associated with a high likelihood of subclinical atherosclerosis by CAC, but it is rarely seen for CAC scores < 100. In most patients, low CAC scores appear to obviate the need for subsequent non-invasive testing. Patients with normal perfusion studies,
however, frequently had extensive non-obstructive atherosclerosis by CAC criteria.

Geluk et al. determined the efficiency of a screening protocol based on CAC scores compared with exercise testing in patients with suspected CAD, a normal ECG and troponin levels [43]. A total of 304 patients were enrolled in a screening protocol that included CAC scoring by EBT, and exercise testing. Decision-making was based on CAC scores. When the CAC score was $\geq 400$, coronary angiography was recommended. When the CAC was $< 10$, patients were discharged. Exercise tests were graded as positive, negative or non-diagnostic. The combined endpoint was defined as coronary event or obstructive CAD at coronary angiography. During 12 $\pm$ 4 months, CAC $\geq 400$, 10–399 and $< 10$ were found in 42, 103 and 159 patients and the combined endpoint occurred in 24 (57%), 14 (14%) and 0 patients (0%), respectively. In 22 patients (7%), myocardial perfusion scintigraphy was performed instead of exercise testing due to the inability to perform an exercise test. A positive, non-diagnostic and negative exercise test result was found in 37, 76 and 191 patients, and the combined endpoint occurred in 11 (30%), 15 (20%) and 12 patients (6%), respectively. Receiver–operator characteristics curves showed that the area under the curve of 0.89 (95% CI: 0.85–0.93) for CAC was superior to 0.69 (95% CI: 0.61–0.78) for exercise testing ($P < 0.0001$). The authors concluded that measurement of CAC is an appropriate initial screening test in a well-defined low-risk population with suspected CAD.

The value of zero calcium score in patients presenting with acute chest pain to the emergency department

The use of CAC assessment was briefly discussed in a recent consensus paper on the use of MDCT for acute chest pain [91, 92]. The use of CAC screening has been described in patients with angina-like symptoms and negative cardiac enzymes presenting to the emergency department (ED). Laudon et al. performed CAC scoring in the emergency department in 104 patients, and noted a negative predictive value for CAD of 100% for a CAC score of zero [93]. McLaughlin et al. reported a negative predictive value of 98% in 134 patients in a similar ED setting [94]. Georgiou et al. followed 198 patients presenting to the ED with chest pain and normal ECG and cardiac enzymes and found that the presence of any CAC is a strong predictor for future cardiac events. Conversely, patients without CAC may safely be discharged from the ED given the extremely low rate of future events ($\sim 0.1%/year$) [41]. Nonetheless, after reviewing the available evidence, Andrews concluded that currently existing data do not sufficiently support the widespread use of CAC CT in patients with acute chest pain syndromes [95]. Even so, in patients at low pre-test likelihood of CAD presenting with angina-like symptoms to the ED, a negative CAC score can possibly be used to rule out an acute coronary syndrome. In conclusion, the available single center studies based on a limited number of patients indicate that the negative predictive value of a zero CAC is high ($> 90\%$). However, the positive predictive value is somewhat lower, rendering CAC screening a highly sensitive, but poorly specific modality for the diagnosis of acute coronary syndromes.

**Calcium score progression: interpretation**

Serial changes in CAC score may have important implications for monitoring the response of atherosclerotic disease to the initiation of or changes in plaque-altering medical therapy as well as for identifying patients with more aggressive disease who are at high risk for incident CAD [4]. In this section, we will discuss the methodological approaches to calculating CAC progression as well as provide a synopsis of the available literature on the utility of sequential CT imaging to evaluate atherosclerotic disease progression.

**Serial testing paradigm**

Serial testing is based on the concept that changes in CAC are valid markers of varying atherosclerotic disease states [96]. Furthermore, a change in CAC may serve as a surrogate for clinical outcomes or disease activity and, as such, provides clinically useful information to guide further patient management [97–102]. The paradigm of using imaging as a surrogate outcome has been advanced in the oncologic PET literature [103]. The response evaluation criteria in solid tumors (RECIST) provide definable
criteria for partial or complete response to therapies of target and non-target lesions.

Using this type of sequential monitoring, a positive change in CAC score above a given threshold signifies progressive disease, minimal or no changes in CAC score identify patients with stable disease, while a reduction in CAC score beyond a given limit defines patients exhibiting regression in their underlying disease. With regards to the latter, it is still very controversial whether CAC truly regresses. As such, this document will focus on defining rapidly and slowly progressive disease states.

Reproducibility of CAC CT and its determinants

A major consideration for interpretation of changes in CAC between serial CT examinations is the variability of repeat imaging. Inter-examination variability is affected by image artifacts including motion, noise, and partial volume averaging that are highly dependent on the specific imaging protocol as well as the extent of CAC burden. Optimal timing of ECG triggering can reduce variability of Agatston scores > 30 to < 15% with EBT [104–106]. The correlation coefficients across CAC measurements, including Agatston score (AU), CVS, or MS, are excellent ($r \geq 0.96, N = 161$) [11, 107]. CVS’s improve reproducibility only marginally compared to Agatston scores. The square root of the CVS has, however, been suggested to reduce inter-examination variability [108].

Differences between types of CT systems are very small after adjustment for body mass index and CAC burden [10]. In the MESA study, mean relative differences between CT examinations at different times were 20.1% for the Agatston score, and 18.3% for the interpolated CVS ($P < 0.01$) [10], which are in line with previous reports. Of note these data were obtained from CT performed at 80% of the RR-interval, which is associated with a lower reproducibility as compared to earlier triggering.

Data acquired with 4-slice CT systems were reported to have higher rates of mis-registration compared with EBT [10]. Motion artifacts were also higher in these CT systems compared to EBT machines, while image noise was lower [10]. The reproducibility of the calcium score has improved with the introduction of 16-slice and more recently 64-slice MDCT systems. The variability is best with thinner slices, higher calcium scores and with retrospective acquisition mode, although this is associated with a higher radiation dose for the patient. Currently, the reported variability of the Agatston, volume and mass score on 16–64-slice MDCT ranges between 8 and 18% (lower end of the range with 64 slice MDCT) on sequential examinations performed within minutes of each other [109–111]. Given the radiation exposure, especially with MDCT systems, the benefit-risk ratio and time intervals of repeat CT must be considered individually, especially when women and young men are examined.

Clinical thresholds of coronary artery calcium progression

Progression of CAC is generally calculated as a percent or absolute change from the baseline score using either the Agatston score, CVS, or MS [99, 104, 112–119]. Raggi et al. defined a change > 15% as true progression [98], while Hokanson et al. suggested a CAC progression $\geq 2.5 \text{ mm}^3$ of the square root of the initial volume score as a useful threshold of progression [108].

The absolute change in CAC is expected to be greater in patients with a higher baseline score (Figs. 3 and 4) [98, 115, 116], although the absolute differences reflect minor changes compared to baseline. Larger percent score changes are expected in patients with a low index CAC score (e.g., index CAC score of 10 to repeat score of 20 = progression of 100%) and do not necessarily reflect a clinically relevant change.

Clinical interpretation of changes in coronary artery calcium

For most patients within the various risk groups in Fig. 5, the error in score reproducibility would not affect their clinical management, unless scores are close to adjacent risk groups. Variability increases with CAC score and may be as much as 200–380 units for scores of 400 or higher (Fig. 5) [120]. As scores of 100 or 400 may trigger more aggressive post-screening management or follow-up ischemia testing, clinicians should rely less on the absolute thresholds and more on a combination of CAC score
with the patient’s clinical presentation and cardiac risk factor profile. Aggressive management is indicated for scores of 1,000 or higher (very high risk CAC) and it is unlikely that the expected variability about this point estimate will change clinical care [99, 104, 112–119].

Rates of coronary artery calcium progression and its determinants

In subjects at average Framingham risk the annual CAC progression rates typically range from 20% to 24% per year using either the Agatston or the CVS [99, 104, 112–119]. Factors that may significantly modify rate of change include the patient’s baseline CAC score, gender, age, family history of premature CAD, ethnicity, diabetes and glycemic control, body mass index, hypertension, and renal insufficiency [98, 121–125]. Further, the longer the interval from baseline to repeat CAC CT, the greater the expected change [117]. However, the absolute change will be greater but the relative change may be smaller. The score does not continue to grow exponentially and the rate of growth eventually tapers off. Most patients exhibit a positive change in CAC scores over time [99, 112–114, 116, 118] although some patients (29–34%) exhibit no change if they are at low Framingham risk, including women, or have a baseline score of 0 (38%) [114]. In patients with an initial 0 score, a repeat CT < 5 years after the initial examination may not be useful for clinical purposes [114].

Results of randomized clinical trials on effect of statin therapy on coronary artery calcium progression

A number of observational studies (Table 3) and randomized clinical trials (Fig. 6) have evaluated change in CAC following treatment with statin therapy. In four observational reports untreated patients had an average CAC score progression of 36% [98, 126–128]. By comparison, statin therapy attenuated changes in CAC scores averaging 13% (Table 3) [98, 126–128].

However, these promising observational data were contradicted by large randomized clinical trials showing similar changes in CAC scores following placebo and/or moderate-intensive statin therapy (Fig. 6). Except for a preliminary pilot trial [129], all other randomized trials have failed to confirm the preliminary observational findings (Fig. 6). Comparison of intensive versus moderate statin therapy showed no difference in CAC progression (Fig. 6) [100, 130]. The lack of an effect in these clinical trials suggests that a longer observational time period may be warranted and that statins may reduce cardiac
events independent of an effect on calcified plaque [4]. Further, these trials often did not consider or plan the management of other CV risk factors that may confound the lack of therapeutic benefit [4]. There are ongoing trials using CAC as a surrogate where additional evidence may be put forth on the benefit in serial imaging [131, 132]. Finally, other treatments have been tested as far as an effect on CAC progression. In the Women’s Health Initiative (WHI), menopausal women between the ages of 50–59 years were randomized to treatment with conjugated estrogens or placebo [133]. In a sub-study

### Table 3

Percent yearly progression from observational cohorts of consecutive patient series, with average Framingham risk, and evidence of coronary artery calcium (CAC) on baseline CT

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>N</th>
<th>Entry criteria</th>
<th>Score</th>
<th>Testing period (in years)</th>
<th>Percent change CAC score/yeara</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budoff et al. [126]</td>
<td>2000</td>
<td>299</td>
<td>Consecutive pts.</td>
<td>AU</td>
<td>≥1</td>
<td>33%</td>
</tr>
</tbody>
</table>
| Shemesh et al. [117]    | 2001 | 116| Asymptomatic hypertensive pts.  | AU    | 1, 2, 3                   | Yr. 1: 18%  
                                |       |    |                                 | CVS   | 29%                       | Yr 2: 31%  
                                |       |    |                                 |       |                           | Yr 3: 41%  |
| Sutton-Tyrrell et al. [118] | 2001 | 80 | Middle-aged women              | AU    | 1.5                       | 11%                            |
| Yoon et al. [119]       | 2002 | 217| Consecutive subjects           | AU    | 2.1                       | 34%                            |
| Raggi et al. [99]       | 2003 | 772| Consecutive pts.               | CVS   | 2.2                       | 26%                            |
| Hsia et al. [115]       | 2004 | 94 | Healthy post-menopausal women  | AU    | 3.3                       | 27%                            |
| Budoff et al. [113]     | 2005 | 177| Post-menopausal pts.           | AU    | ≥1                        | 15%–22%                        |
| Rasouli et al. [116]    | 2005 | 133| Asymptomatic pts.             | AU    | 1.7                       | 17%–22%                        |
| Gopal et al. [114]      | 2006 | 710| Consecutive pts. w/CAC = 0    | AU    | ≥1                        | Mean ± sd: 1 ± 3  
                                |       |    |                                 | CVS   |                           | Median (IQR): 0 (0–0.8) |
| Becker et al. [112]     | 2007 | 277| Post-menopausal women          | CVS   | 3.3                       | 18%                            |
| Summary data            | 2,875|    |                                 | AU    |                           | 20%                            |
|                         |      |    |                                 | CVS   |                           | 24%                            |

Abbreviations: CAC = Coronary Artery Calcium, year = year, AU = Agatston units, CVS = calcium volume score, s.d. = standard deviation

### Fig. 6

Summary meta-analysis of randomized control trials (RCT) on the effect of Statin therapy (Rx) on CAC progression

#### RCTs of Statin Therapy vs. Placebo

<table>
<thead>
<tr>
<th>Studies:</th>
<th>Baseline CAC Change / yr</th>
<th>Rate Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achenbach [18]</td>
<td>155*</td>
<td>25:11 relative</td>
</tr>
<tr>
<td>Arad [19]</td>
<td>563:527</td>
<td>240:192</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.39</td>
</tr>
</tbody>
</table>

* Achenbach - Patients had a Treated and Untreated Time Period. Thus Statin vs. Placebo and no summary effect was calculated.

#### RCTs of Moderate vs. Intensive Statin Therapy

<table>
<thead>
<tr>
<th>Studies:</th>
<th>Baseline CAC Change / yr</th>
<th>Rate Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmermund [130]</td>
<td>366 CVS</td>
<td>267:205</td>
</tr>
<tr>
<td></td>
<td></td>
<td>relative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>relative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.48 (-0.2% to 11.5%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.85</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.40</td>
</tr>
</tbody>
</table>

*Abbreviations: CAC=Coronary Artery Calcium, CVS=Calcium Volume Score, AU=Agatston Units, RCT=Randomized Clinical Trial, Yr=Year,*
of the WHI, 1,064 women were submitted to CAC screening after 8.7 years from trial initiation. Women receiving estrogens showed a lower CAC score compared to those receiving placebo (83.1 vs. 123.1, \( P = 0.02 \)).

**Cardiovascular prognosis related to coronary artery calcium progression**

Despite the lack of an effect of statins on CAC progression, several reports have noted that a rapid change in CAC score is associated with worse clinical outcomes including incident MI [97, 99]. In one report of 495 patients, subjects who experienced an acute MI experienced greater degrees of CAC progression compared to event-free survivors (42% ± 23% vs. 17% ± 25%, \( P < 0.0001 \)) [97]. Patients with and without > 15%/year change in CAC score had 66% and 97% MI-free survival, respectively, at 6 years (\( P < 0.0001 \)). Patients who exhibited significant progression from their index CT (\( \geq 15%/\text{year} \)) and those with baseline CAC score \( \geq 400 \) had a more rapid presentation to acute MI occurring at 2–4 years post-testing as compared to those with CAC scores \( \leq 100 \) with incident MI’s at over 5 years from baseline testing (\( P < 0.0001 \)). Thus, the baseline CAC score provides an insight into not only the expected rate of progression but also the timeline of conversion to symptomatic CAD.

**Summary**

The evidence is inconclusive as to what is the most accurate method to define CAC progression (percent versus absolute versus square root change). Further research is indicated as to documenting meaningful changes in the various scores. For the patient with an average FRS, the yearly increase in CAC score is approximately 15–20%. Absolute changes are greater in patients whose baseline score exceeds 100. To date, published randomized trials have failed to demonstrate a benefit of statin therapy to attenuate CAC progression. Despite this, rapidly increasing CAC scores may be used to define higher risk patients. Further insight into the prognostic implications of serial CT examinations is warranted to further guide optimal patient management. This writing committee does not recommend the systematic performance of serial CAC scoring in every patient that has undergone a baseline CT and is receiving treatment for factors related to atherosclerosis. An individualized approach to assess rate of progression in specific situations may be taken into consideration.

**Standardization of the calcium score measured using different CT systems**

The utilization of CAC scores for outcomes data, risk stratification, and particularly, the serial assessment of patients over time demands accurate measurements. Accurate measurement of MDCT derived CAC scores requires implementation of standardized imaging and quantification methods on many different types of commercially available MDCT systems. This formidable goal can be achieved by selecting CT parameters that fulfill minimum requirements for temporal resolution, spatial resolution, and noise and by applying a physically meaningful, calibration-based calcium quantification algorithm.

A standard for CAC quantification was recently proposed by the Physics Task Group of the International Consortium on Standardization in Cardiac CT and is reviewed here [6]. Standardized CT protocols were developed for six CT models from five manufacturers (Aquilion, Toshiba Medical Systems, Nasu, Japan; Imatron, Imatron San Francisco, CA; Lightspeed Plus, General Electric Healthcare, Milwaukee, Wisconsin; MX8000, Philips Medical Systems, Best, The Netherlands; Volume Zoom, Siemens Medical Solutions, Erlangen, Germany; Sensation 64, Siemens) using an anthropomorphic cardiac phantom containing water and calcium inserts and capable of simulating three patient sizes. Manufacturer recommended protocols met the minimum requirements for imaging coronary calcium with MDCT: (1) acquisition of at least four slices per rotation, (2) rotation time less than or equal to 0.5 s, (3) ability to reference data acquisition or reconstruction to the ECG signal. Most protocols were, however, modified to achieve a target noise level (20–23 HU) in the water insert for each phantom size. This primarily required determination of CT model- and size-specific values for the tube current (mA) or tube-current time product (mAs). Small, medium, and large anthropomorphic phantoms were then examined on a total of 10 different CT machines using these standardized CT protocols.
All image sets were scored using a single software package because, although not explicitly evaluated by the Consortium, differences among scoring packages are assumed to be non-negligible (but low compared to other sources of error; see next section). To address this issue, software manufacturers were asked to modify existing algorithms according to recommendations of the Consortium. Software packages will then be validated as they become available (at least three manufacturers have incorporated the Consortium recommendations into their software at this writing).

To quantify CAC, voxels containing calcium were first isolated from other tissue and image noise primarily by applying a standard 130 HU attenuation threshold to the reconstructed images. Agatston, volume, and mass scores were then calculated using standard quantification algorithms [6]. To obtain absolute values for calcium mass, a calibration measurement of a calcification with known hydroxyapatite (HA) density was carried out and a calibration factor determined. Because the CT number of all materials except water depends on the X-ray spectrum, a specific calibration factor exists for each machine and each CT protocol. Work by the Physics Group of the Consortium also showed that patient size changes the X-ray spectrum and impacts the value of the calibration factor significantly. Therefore, a unique calibration factor was determined for each of three broad categories of patient sizes for each CT model and each CT protocol using the cardiac phantom’s water and calcium inserts.

The mass score ($m_{ij}$) was then computed as the product of the appropriate calibration factor ($c_{HA}$), the number of voxels containing calcium ($N_{voxel}$), the volume of one voxel ($V_{voxel}$), and the mean CT number for each lesion ($CT_{ij}$): 

$$m_{ij} = c_{HA} \cdot N_{voxel} \cdot V_{voxel} \cdot CT_{ij}$$

The total mass score is the sum of the mass of all individual lesions.

Analysis of the mean and standard deviation of the calcium scores measured under ideal conditions from EBCT and MDCT systems demonstrated a coefficient of variation of 4.0% for Agatston scores, 7.9% for volume scores, and 4.9% for mass scores. The accuracy, or exact correspondence between measured and true values, could not be assessed for Agatston scores because this score represents only a mathematical construct and as such cannot be compared to a physical reference standard. However, calcium volume and mass scores could be compared to known values from the cardiac phantom. For the five MDCT systems, the total calcium mass score was within ± 5 mg of the total known mass of calcium HA within the phantom (168.2 mg). The accuracy of EBT measurement was considerably worse (mean mass score equaled 182.7 mg). Therefore, the increased precision of the mass score as compared with the volume score and the ability to compare the measured mass score with a known physical standard motivated the Consortium to endorse the mass score approach as the preferred method of quantifying CAC.

Additional data have been collected by the Physics group towards optimization of the mass score. Specifically, the requirements for calculation of a calibration factor were examined. Variation in the measured calibration factor from three sizes of the anthropomorphic cardiac phantom was assessed across CT machines, time, and patient sizes. Assessment across CT machines, revealed the coefficient of variation in the calibration factor was small for a specific CT manufacturer and CT model (0.13–1.6%). Subsequent data analysis from the same CT systems over time has shown slightly higher variation for measurements made quarterly over a 4-year period from a single 16-slice CT machine (2.8–3.2%) and over a 2-year period from a single 64-slice CT machine (2.5–3.1). The change in phantom (i.e., patient size), however, caused a much larger change in calibration factor both across CT systems (3.8–5.1%) and over time (3.4–5.0%). Therefore, determination of a calibration factor for a given CT machine and patient size from quarterly CT of an anthropomorphic phantom should be sufficiently stable over time to permit 3% or less variation in the measurement. It has been suggested that inclusion of a calibration insert with each patient is necessary for precise measurement of a calibration factor. However, this seems unnecessary based on the low variability in calibration estimation with quarterly anthropomorphic CT.

Because of the variation in calibration measurements, particularly across patient sizes, the consortium recommended identifying voxels containing calcium by applying a threshold based on a fixed density or concentration of calcium HA (100 mg/cc of calcium...
HA) rather than the traditional fixed attenuation (130 HU) that may not provide a consistent cutoff value for calcium across examinations.

In summary, the Physics Group demonstrated that standardized protocols and algorithms can provide accurate and precise calcium mass scores in phantoms independent of MDCT model and phantom (patient) size through the use of appropriate calibration factors. Implementation of these protocols should move the field of CAC scoring closer to the realization of meaningful quantitative comparisons of CAC scores measured over time within a patient and across patients even when imaging is performed using different MDCT models. An obvious output of the implementation of such standards should be reduced variability in CAC measurements although this remains a point of investigation.

The recommendations of the Consortium have largely been implemented by the CT manufacturers making adherence to these standardization procedures in clinical CT straightforward. Additional relatively tasks beyond current practice will, however, be required including measurement of lateral skin-to-skin width at mid-liver from an anteroposterior CT radiograph (“scout” image) to assess patient size, selection of appropriate patient-size specific mA/mAs to achieve the noise target, and selection of appropriate patient-size specific calibration factor to determine a density-based attenuation threshold and calculate absolute calcium mass.

The biggest obstacle to widespread use of the mass score is the paucity of data available for clinical decision-making. The CAC score is most clinically meaningful in the context of risk-stratification which requires referencing a patient’s total CAC score to age- and sex-matched data. A patient is assigned to a percentile range of risk on the basis of his or her total CAC score; the percentile range is defined by flexible thresholds that take into account the independent effects of age and sex on the amount of total CAC. Most currently available databases, particularly those with a significant number of patients, contain only Agatston scores. An MDCT database founded upon standard protocols using the mass score is therefore necessary.

Implementation of a standardization procedure for the acquisition and analysis of CAC images permits the accumulation of scores from various MDCT systems in a single database. A web-based database has been developed through the efforts of the Consortium to allow collection of standardized MDCT patient risk factor and CAC data (https://clinapps.bio.ri.ccf.org/cascore/). A sufficient number of patients must be entered before assignment of a precise percentile ranking can be provided to an individual patient. Based on early data, it was determined that a total registry size of 4,000 would be sufficient to estimate the percentile ranking of future patients in the age range of 45–70 years. To date, data from over 1,000 patients have been collected. The Writing Group supports this standardization procedure and recommends that this registry be supported.

Influence of scoring parameter settings of underlying software algorithms on calcium scoring

All scoring methods used for the determination of CAC have a common denominator. This is the algorithm used to determine which areas above the threshold HU value are calcified lesions and which can be discarded as noise. To determine this very important distinction, common algorithms are used that are influenced by a number of different parameter settings which, as shown by van Ooijen et al. in 50 patients imaged with EBT, influence the resulting CAC score [134]. The most common parameters are the HU threshold value, the connectivity, the lesion size threshold and the use of interpolation. Some commercially available software packages provide the user with the parameter settings and even allow changing these parameters. Others hide the default settings and determining the settings used can be very difficult. Mean variability can be up to 15–16 points for the Agatston score with the largest influence coming from changing the lesion size threshold between 2 and 4 pixels. For the CVS, mean variability can be up to 20–30 points largely due to the effect of changing the lesion size threshold between 2 and 4 pixels and from turning interpolation on and off. It could well be that the effect of interpolation will be less prominent when using MDCT instead of EBT because of the use of slice overlap. There are no published data for the mass scoring method, but since this method also relies on algorithms to determine what regions are lesions and what regions are not, it is likely that similar results will be found.
In conclusion, when performing CAC scoring based on the volume or Agatston score, software parameter settings affect the outcome. Furthermore, the use of new software versions or other software packages and the use of data acquired in other institutes in the follow-up of patients could also affect the measured progression or regression of CAC because of different parameter settings. These data show, therefore, that not only standardization of CT protocols is obligatory, but CAC scoring parameters also need to be standardized. Further research is required to determine whether using phantom data or test patient datasets can help standardizing settings across software and help selecting the appropriate settings of a certain software package when they are unclear.

Radiation exposure

A broad implementation of CAC screening may be limited by factors such as cost, patient access and demonstration of altered medical outcomes. In addition, risks associated with the use of ionizing radiation must be taken into account, especially for younger or female patients or when considering additional radiological tests such as CT and MPI. CAC screening delivers a relatively low radiation dose (effective dose of 0.7 mSv with EBT and 1.0–4.1 mSv with MDCT) [135], while coronary CT angiography (outside of the scope of this writing) delivers somewhat increased levels of radiation dose (effective dose of 9.4 to 14.8 mSv) [136]. The dose to any one individual depends both on the imaging protocol used and the patient’s body habitus. The radiation exposure provided by CAC screening is substantially lower than that of MPI studies (effective dose range of 13–16 mSv), especially those conducted using Thallium–201 or dual isotope techniques (effective dose of 27.3 mSv) [137] or invasive diagnostic coronary catheterization (effective dose of 3–10 mSv) [138].

Much of our knowledge on the carcinogenic effects of low doses of radiation (whole body exposures of 5–150 mSv) derives from follow-up data on the survivors of the atomic bombings in Japan. Although quite small, there appears to be an increase in incidence of cancer in subjects exposed to low doses of radiation, especially in children—because of the higher radiation sensitivity and the longer available time for cancer development after exposure. Using the linear non-threshold model of radiation induced risk and the organ specific risk from Biological Effects of Ionizing Radiation (BEIR VII) [139], the data presented by Einstein et al. [140] can be linearly scaled to predict the lifetime risk of cancer. Assuming a factor of 10 reduction of dose from a coronary CTA exam, the lifetime risk of cancer for a CAC CT in a 50-year-old individual is 0.04% for a man and 0.12% for a woman. To properly interpret these data, the individual’s complete risk profile must be considered, including the background risk of cancer incidence in the general population and any individual-specific risks such as diabetes, high blood pressure or a family history of cancer or heart disease. According to statistics from the American Cancer Society, the lifetime risk of cancer at any site is 45% for men and 38% for women; the respective death rates are 23 and 20% [141]. Thus, taking into account the patient’s specific medical risks, particularly of CAD, and the background population risks, the additive cancer risk from a CAC exam is negligible, provided that some benefit may be gained from the examination. Thus, this committee of experts does not support the application of CAC screening to individuals at low risk of CAD, where medical benefit is not expected. For individuals at intermediate risk of CAD, the small statistical risk of cancer induction and death is very low relative to the patient’s complete risk profile. In these patients, the potential benefit to the patient from knowledge obtained in the CAC exam greatly exceeds the small potential risk of cancer and the use of CAC screening is recommended in several clinical scenarios.

Further, in contrast to alarming media reports regarding the risks associated with ionizing radiation, the radiation biology and epidemiology community is divided as to the actual degree of risk at the low doses associated with medical imaging examinations. Considering the error bars associated with the data from the Japanese bomb survivors, the difficulty in transferring risk estimates between population cohorts and irradiation dose rates and types (high versus low dose rates, whole body versus partial body exposures, etc.), and the conflicting reports from medically exposed populations that show no increase in risk at medical imaging dose levels, it is the official
position of the Health Physics Society that meaningful risk estimates are not possible below effective doses of 100 mSv [142]. Thus, CAC exams, with effective doses of 1–4 mSv, may be in fact be associated with no additional risk and hence should not be avoided when information important to the patient’s medical management may be obtained.

Conclusions

The writing committee would like to summarize in a series of conceptual points the evidence discussed herein as follows.

We know and support the conclusion that:

- CAC is a good predictor of events in Caucasians and adds incremental prognostic value to risk factors in intermediate risk populations
- There is significant variability between ethnicities in the prevalence and extent of coronary calcium.
- Absence of CAC is associated with very low event rates in most risk categories
- Rapid CAC progression is associated with higher risk of events
- CAC is a strong predictor of events in end stage renal disease
- A zero calcium score is associated with a very low prevalence of ischemia on functional stress testing and obstructive disease on angiography

We are beginning to understand that:

- CAC may have good predictive value in the elderly, diabetic patients and patients of different ethnic background
- CAC scores can be used to predict presence of obstructive CAD but despite a high sensitivity this tool demonstrates a low specificity; hence the main utilization of CAC should be assessment of risk of cardiovascular events rather than the detection of severe CAD

We still need to prove that:

- We can alter CAC progression with medical interventions
- Altering CAC progression with medical interventions impacts patients’ outcome
- We may not need to treat patients with risk factors in the absence of CAC

Finally, standardized procedures for both image acquisition and CAC scoring should be followed so that we might best advance our knowledge using MDCT.

Disclosure of support SSH—None; WAK—Siemens Medical Solutions; CHM—Bayer Healthcare, Siemens Medical Solutions; RTI Electronics, Inc; SM—None; MO—None; PMAO—None; PR—None; AES—Astellas, Siemens Medical Solutions; LJS—None; WS—None; AJT—None; RV—None; LW—None.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References


